Name : Biotinylated Human ALCAM/CD166 Protein (Primary Amine Labeling)
Product Source :
Recombinant Biotinylated Human ALCAM/CD166 Protein (Primary Amine Labeling) is expressed from HEK293 with His tag at the C-Terminus. It contains Trp28-Ala526.[Accession | Q13740-1]
Molecular Weight :
The protein has a predicted MW of 57 kDa. Due to glycosylation, the protein migrates to 70-80 kDa based on Tris-Bis PAGE result.
Endotoxin Level :
Less than 1EU per ug by the LAL method.
Purity :
> 95% as determined by Tris-Bis PAGE
Formulation :
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution :
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage and Stability :
-20 to -80°C for 12 months as supplied from date of receipt.-80°C for 3-6 months after reconstitution.2-8°C for 2-7 days after reconstitution.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Product Concentration :
Tris-Bis PAGE Biotinylated Human ALCAM (Primary Amine Labeling) on Tris-Bis PAGE under reduced condition. The purity is greater than 95%. ELISA Data Immobilized Anti-ALCAM Antibody, hFc Tag at 5μg/ml (100μl/well) on the plate. Dose response curve for Biotinylated Human ALCAM, His Tag with the EC50 of 1.6μg/ml determined by ELISA.
Background :
Brain metastasis (BM) in non-small-cell lung cancer (NSCLC) has a very poor prognosis. Recent studies have demonstrated the importance of cell adhesion molecules in tumor metastasis.Elevated levels of ALCAM expression promote BM formation in NSCLC through increased tumor cell dissemination and interaction with the brain endothelial cells. Therefore, ALCAM could be targeted to reduce the occurrence of BM.
Synonyms :
CD166; ALCAM; MEMD; CD6L; KG-CAM
References & Citations :
(1) Münsterberg J, Loreth D, Brylka L, Werner S, Karbanova J, Gandrass M, Schneegans S, Besler K, Hamester F, Robador JR, Bauer AT, Schneider SW, Wrage M, Lamszus K, Matschke J, Vashist Y, Uzunoglu G, Steurer S, Horst AK, Oliveira-Ferrer L, Glatzel M, Schinke T, Corbeil D, Pantel K, Maire C, Wikman H. ALCAM contributes to brain metastasis formation in non-small-cell lung cancer through interaction with the vascular endothelium. Neuro Oncol. 2020 Jul 7;22(7):955-966. doi: 10.1093/neuonc/noaa028. PMID: 32064501; PMCID: PMC7339886.
Related category websites: https://www.medchemexpress.com/recombinant-proteins.html
Popular product recommendations:
CRELD1 ProteinPurity & Documentation
CD79B ProteinFormulation
Popular categories:
IL-1 alpha
VLA-5